Can a Faecal Transplant Help IBS? What New Research Says About FMT and the Microbiome
- Aleks Jagiello BSc, MSc, RD
- 4 days ago
- 8 min read
Concise answer
Faecal microbiota transplantation, often called FMT or a stool transplant, is being studied for IBS, but it is not currently a routine treatment for IBS.
A new 2026 systematic review and meta-analysis of randomised controlled trials in Gastroenterology has updated the evidence, but the overall picture remains mixed. Some studies suggest symptom improvement in selected groups, while others show little or no clear benefit compared with placebo.
For now, FMT should be viewed as an emerging microbiome therapy, rather than a standard IBS treatment to try outside specialist or research settings.
What is a faecal microbiota transplant?
A faecal microbiota transplant is a medical treatment where stool from a carefully screened healthy donor is processed and transferred into another person’s gut.
The aim is to change the recipient’s gut microbial community.
FMT can be delivered in different ways, including capsules, tubes into the upper gut, colonoscopy, or enema-based approaches. Research trials in IBS have used different methods, which makes the evidence harder to compare directly.
You may also hear it called:
FMT
stool transplant
faecal transplant
faecal microbial transplant
microbiota transfer
FMT has a clearer role in some other gut conditions, especially recurrent Clostridioides difficile infection, but IBS is a different situation. IBS is a disorder of gut-brain interaction, involving gut sensitivity, motility, immune signalling, food responses, stress physiology, and the microbiome.
Why are researchers studying FMT for IBS?
Researchers are interested in FMT because IBS has been linked with changes in the gut microbiome.
Some people with IBS show differences in gut bacteria compared with people without IBS, and symptoms such as bloating, diarrhoea, constipation, abdominal pain, and urgency can be influenced by fermentation, gas handling, gut sensitivity, and motility.
The tricky part is this: a difference in the microbiome does not automatically tell us what caused the symptoms or how to treat them.
IBS symptoms can be influenced by several overlapping factors, including:
fermentable carbohydrates such as FODMAPs
stool consistency and transit time
visceral hypersensitivity
gut-brain axis signalling
post-infectious changes
bile acid issues in some diarrhoea-predominant cases
constipation with incomplete emptying
sleep, stress, and routine changes
gut microbial activity
FMT research is investigating whether altering the microbial environment can reduce IBS symptoms in a meaningful, lasting way.
What did the new 2026 research find?
A new systematic review and meta-analysis published in Gastroenterology in May 2026 reviewed randomised controlled trial evidence on FMT for IBS.
This matters because randomised controlled trials are more useful than anecdotes, testimonials, or before-and-after stories when we are trying to understand whether a treatment works beyond placebo response and natural symptom fluctuation.
The updated review builds on earlier meta-analyses, which have found mixed results.
A 2024 meta-analysis in BMC Gastroenterology included randomised controlled trials in adults diagnosed with IBS using Rome III or Rome IV criteria. It found that, overall, FMT did not show a statistically significant global improvement in IBS symptoms at 12 weeks or 52 weeks compared with placebo, although there were signals in some subgroup analyses and in quality-of-life outcomes.
The same 2024 review also highlighted a key issue: FMT studies vary a lot. Differences include:
how donors are selected
whether stool comes from one donor or multiple donors
how the transplant is delivered
the dose used
whether patients have IBS-D, IBS-C, IBS-M, or predominant bloating
how long people are followed up
what outcome measure is used
This variation makes it harder to give a simple answer, such as “FMT works” or “FMT does not work”.
A more clinically useful interpretation is:
FMT may help some people with IBS in some research settings, but we do not yet have enough clarity to know who is most likely to benefit, which protocol is best, and whether benefits are consistent long-term.
Could FMT help with bloating?
Possibly for some people, but this is still uncertain.
One placebo-controlled randomised trial looked specifically at people with IBS and predominant abdominal bloating and reported symptom reduction in some participants after FMT.
This is interesting because bloating is one of the most common and frustrating IBS symptoms, and it is often the one that drives people to seek microbiome-based solutions.
However, bloating is not always caused by the same mechanism.
Bloating may be related to:
constipation or incomplete evacuation
visceral hypersensitivity
gas production from fermentable carbohydrates
abdomino-phrenic dyssynergia
meal size or eating speed
gut-brain axis activation
hormonal changes
pelvic floor dysfunction
food-related fermentation
altered gut transit
Because bloating has several possible drivers, a microbiome-focused therapy may not be the right answer for everyone.
Is FMT currently recommended for IBS?
At the moment, FMT is not a standard first-line IBS treatment in major IBS management guidance.
NICE guidance for IBS focuses on confirming the diagnosis, checking for red flags, considering basic investigations where appropriate, and using diet, lifestyle, medication, and psychological approaches depending on symptoms.
The British Dietetic Association recommends starting with practical dietary and lifestyle strategies, including regular meals, adequate fluid intake, moderation of caffeine/alcohol/fizzy drinks where relevant, symptom diaries, and specialist dietetic support if symptoms persist or dietary intake becomes restricted.
The British Society of Gastroenterology guideline also supports a positive diagnosis of IBS and evidence-based management, including dietetic approaches, low FODMAP diet with appropriate supervision, gut-brain therapies, and symptom-targeted treatments.
So, FMT is best understood as an emerging therapy under investigation, rather than as something to pursue in routine IBS care.
Is FMT safe?
FMT should only be considered in medical or research settings with appropriate donor screening and clinical oversight.
In IBS trials, adverse events are often gastrointestinal, such as abdominal discomfort, diarrhoea, constipation, nausea, cramping, or bloating. A 2024 meta-analysis found no significant difference in total adverse events overall, but constipation and abdominal pain were higher in the FMT group in the analysed data.
There are also wider safety concerns in FMT literature, including the potential transmission of infections if donor screening is inadequate. Serious infection transmission has been reported in FMT literature outside the IBS context, which is why medical screening and regulation matter.
FMT is not something to attempt at home.
Online “DIY stool transplant” discussions can make FMT sound like a microbiome reset, but IBS care should never involve unscreened donor stool, informal protocols, or advice from non-clinical internet sources.
Should I do a gut microbiome test before considering IBS treatment?
For most people with IBS, commercial microbiome tests do not yet give clear, validated, treatment-changing answers.
They may show bacterial patterns, but they usually cannot tell you:
your exact IBS trigger
whether low FODMAP will work
which probiotic will help
whether your bloating is from gas, constipation, sensitivity, or pelvic floor factors
whether you need FMT
what your personalised IBS treatment plan should be
Microbiome science is advancing quickly, but clinical IBS care still depends on a careful symptom history, medical screening where appropriate, stool pattern assessment, dietary assessment, and an understanding of the person’s real-life routines.
Are probiotics a safer alternative to FMT?
Probiotics are very different from FMT. A probiotic usually provides selected strains of bacteria, while FMT transfers a much more complex microbial community from donor stool.
The evidence for probiotics in IBS is mixed and strain-specific. The BDA suggests trying one probiotic at a time for at least four weeks while monitoring symptoms.
The British Society of Gastroenterology guideline suggests people who want to try probiotics can consider them for up to 12 weeks and stop if there is no response.
Monash University has also highlighted that probiotic research in IBS varies across strains, doses, populations, and outcomes, making it difficult to provide a single universal recommendation.
So probiotics may be worth considering in some cases, but they are not a guaranteed fix for IBS.
What this means for people with IBS
If you are reading about FMT because you feel stuck with IBS, the main message is this:
The microbiome matters, but IBS treatment usually needs more than a microbiome-focused solution.
This is especially true if your symptoms involve:
bloating that changes through the day
constipation with incomplete emptying
diarrhoea or urgency after meals
flare-ups during stressful periods
symptoms despite eating carefully
fear around food
repeated attempts at probiotics or gut-health supplements
confusion after trying parts of the low FODMAP diet without clear guidance
FMT research is interesting and may become more relevant to selected IBS subgroups in the future. Right now, the evidence is not clear enough for it to replace structured IBS care.
What should you focus on before microbiome treatments?
A more practical starting point is to ask:
Have I had the right checks?
IBS can be diagnosed positively, but red flags and other conditions should be considered. NICE recommends assessment for concerning features and basic investigations where appropriate, including markers for inflammation and coeliac disease testing in the right clinical context.
Do my symptoms match my IBS subtype?
IBS-D, IBS-C, IBS-M, and IBS with predominant bloating can behave very differently.
For example, diarrhoea can sometimes be linked with constipation overflow, urgency can relate to gastrocolic reflex sensitivity, and bloating may be driven by stool burden, gas handling, or sensitivity rather than food intolerance alone.
Have I tried dietary changes in a structured way?
Jumping between gluten-free, dairy-free, low FODMAP, probiotic drinks, gut powders, and random online rules often creates more confusion.
A structured plan may include:
regular meals
fibre type and dose review
constipation or diarrhoea-specific strategies
low FODMAP trial and reintroduction if appropriate
checking FODMAP stacking
assessing caffeine, alcohol, and high-fat meals
realistic meal planning
symptom review without obsessive tracking
Is my nervous system part of the symptom pattern?
IBS symptoms can become more noticeable when sleep, stress, routines, and meal timing are disrupted.
This does not make the symptoms imagined. The gut and brain communicate through nerves, hormones, immune pathways, and microbial signals.
Am I restricting food without getting clearer answers?
If your food list keeps shrinking and symptoms are still unpredictable, more restrictions are rarely the best next step.
At that point, it is often more useful to step back and map symptoms properly.
Practical takeaway
FMT is one of the most interesting areas in IBS microbiome research, but it is not yet ready for routine use as an IBS treatment.
For now:
Do not attempt DIY FMT.
Be cautious with claims that promise to “reset” your gut microbiome.
Use microbiome research as one part of the IBS picture, not the whole explanation.
Focus first on diagnosis, symptom patterns, bowel habits, diet quality, fibre tolerance, suitability for low-FODMAP, stress physiology, and sustainable routines.
Seek personalised support if symptoms remain unpredictable despite trying sensible changes.
If you have tried probiotics, food rules, low-FODMAP lists, or “gut reset” advice and still feel unsure about what is actually driving your symptoms, a structured assessment can make the next step much clearer.
The IBS Clarity Intensive is a 90-minute deep dive into your symptoms, food patterns, bowel habits, routines, and flare-up triggers, so you can leave with a personalised plan.
For longer-term support, the IBS Relief Blueprint provides structured, dietitian-led IBS coaching, including education, implementation support, and personalised guidance.
References:
Aumpan N, Adike A, Acharekar MV, et al. Fecal microbiota transplantation for symptom improvement in patients with irritable bowel syndrome: systematic review and meta-analysis of randomized controlled trials. Gastroenterology. Published online 19 May 2026. DOI: 10.1053/j.gastro.2026.04.039.
PubMed: https://pubmed.ncbi.nlm.nih.gov/42162772/
Journal: https://www.gastrojournal.org/article/S0016-5085%2826%2906874-5/abstract
ScienceDirect: https://www.sciencedirect.com/science/article/pii/S0016508526068745
Wang H, Xu Z, Mei L, et al. A meta-analysis of randomized controlled trials evaluating the effectiveness of fecal microbiota transplantation for patients with irritable bowel syndrome. BMC Gastroenterology. 2024. DOI: 10.1186/s12876-024-03311-x.
https://link.springer.com/article/10.1186/s12876-024-03311-x
Wang M, Wu J, Chen Y, et al. Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Immunology. 2023;14:1136343. DOI: 10.3389/fimmu.2023.1136343.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1136343/full
El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020.
https://pubmed.ncbi.nlm.nih.gov/31852769/
Holvoet T, Joossens M, Vázquez-Castellanos JF, et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology. 2021.
https://pubmed.ncbi.nlm.nih.gov/32681922/
El-Salhy M, Hausken T, Hatlebakk JG. Increasing the dose and/or repeating faecal microbiota transplantation increases the response in patients with irritable bowel syndrome. Nutrients. 2019. https://pubmed.ncbi.nlm.nih.gov/31835622/
El-Salhy M, Hausken T, Hatlebakk JG. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation. Gastroenterology. 2022.
https://pubmed.ncbi.nlm.nih.gov/35709830/
NICE. Irritable bowel syndrome in adults: diagnosis and management. Clinical guideline CG61. Last reviewed April 2025.https://www.nice.org.uk/guidance/cg61/chapter/Recommendations
British Dietetic Association. Irritable bowel syndrome and diet.
https://www.bda.uk.com/resource/irritable-bowel-syndrome-diet.html
Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021. https://pubmed.ncbi.nlm.nih.gov/33903147/
Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology. 2021. https://pubmed.ncbi.nlm.nih.gov/33315591/
Monash University FODMAP. Probiotics and IBS: update.
Comments